Key points are not available for this paper at this time.
Our study suggested that gut microbiota differences changed after biologic therapies among IBD with different disease activity, and a rising Firmicutes/Bacteroidetes ratio could be a potential predictor for disease activity and treatment response monitoring.
Tsai et al. (Wed,) studied this question.